{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:08:54Z","timestamp":1788826134753,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901399"],"award-info":[{"award-number":["81901399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973399"],"award-info":[{"award-number":["81973399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001399"],"award-info":[{"award-number":["82001399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bcp.2023.115939","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T12:17:26Z","timestamp":1700741846000},"page":"115939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"219","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenXin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2023.115939_b0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1016\/j.bcp.2023.115939_b0010","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.3748\/wjg.v21.i26.7933","article-title":"Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries","volume":"21","author":"Domper Arnal","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"suppl 5","key":"10.1016\/j.bcp.2023.115939_b0015","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bcp.2023.115939_b0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2023.115939_b0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5603\/FHC.2013.0036","article-title":"Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy","volume":"51","author":"Wojcik","year":"2013","journal-title":"Folia Histochem Cytobiol"},{"issue":"7","key":"10.1016\/j.bcp.2023.115939_b0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"10.1016\/j.bcp.2023.115939_b0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.bcp.2023.115939_b0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: a novel second-generation proteasome inhibitor","volume":"7","author":"Khan","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.bcp.2023.115939_b0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2019.04.006","article-title":"Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation","volume":"302","author":"Park","year":"2019","journal-title":"J Control Release"},{"issue":"20","key":"10.1016\/j.bcp.2023.115939_b0050","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/1078-0432.CCR-20-1232","article-title":"Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib","volume":"26","author":"Fraunhoffer","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2023.115939_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-014-0111-8","article-title":"Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models","volume":"33","author":"Baker","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2023.115939_b0060","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2023.115939_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12944-018-0697-5","article-title":"Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs","volume":"17","author":"Qureshi","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.bcp.2023.115939_b0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.surg.2007.04.012","article-title":"Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma","volume":"142","author":"Hamner","year":"2007","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.bcp.2023.115939_b0075","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1158\/1535-7163.MCT-11-0555","article-title":"The ubiquitin-proteasome system meets angiogenesis","volume":"11","author":"Rahimi","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.bcp.2023.115939_b0080","doi-asserted-by":"crossref","first-page":"e1534664","DOI":"10.1080\/2162402X.2018.1534664","article-title":"Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5","volume":"8","author":"Carlsten","year":"2019","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115939_b0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00432-015-2047-6","article-title":"Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines","volume":"142","author":"Hanke","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bcp.2023.115939_b0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","article-title":"The role of endoplasmic reticulum stress in human pathology","volume":"10","author":"Oakes","year":"2015","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.bcp.2023.115939_b0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gutjnl-2013-306347","article-title":"ER stress induces epithelial differentiation in the mouse oesophagus","volume":"64","author":"Rosekrans","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2023.115939_b0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fendo.2020.00556","article-title":"Master Regulator Activating Transcription Factor 3 (ATF3) in Metabolic Homeostasis and Cancer","volume":"11","author":"Ku","year":"2020","journal-title":"Front Endocrinol (lausanne)"},{"issue":"31","key":"10.1016\/j.bcp.2023.115939_b0105","doi-asserted-by":"crossref","first-page":"21544","DOI":"10.1074\/jbc.M114.558890","volume":"289","author":"Edagawa","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2023.115939_b0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/cancers13010102","article-title":"Acriflavine, a Potent Inhibitor of HIF-1alpha, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-Hypoxic Conditions","volume":"13","author":"Marti-Diaz","year":"2020","journal-title":"Cancers (basel)"},{"issue":"20","key":"10.1016\/j.bcp.2023.115939_b0115","doi-asserted-by":"crossref","first-page":"e99735","DOI":"10.15252\/embj.201899735","article-title":"Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival","volume":"37","author":"Pathria","year":"2018","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.bcp.2023.115939_b0120","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.bcp.2023.115939_b0125","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/j.1742-4658.2012.08748.x","article-title":"Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma","volume":"279","author":"Sheng","year":"2012","journal-title":"FEBS J"},{"key":"10.1016\/j.bcp.2023.115939_b0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1476-4598-13-101","article-title":"Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma","volume":"13","author":"Girgis","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bcp.2023.115939_b0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cbi.2014.03.001","article-title":"Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma","volume":"215","author":"Mansour","year":"2014","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.bcp.2023.115939_b0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1631\/jzus.B1900551","article-title":"Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression","volume":"21","author":"Yang","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"issue":"13","key":"10.1016\/j.bcp.2023.115939_b0145","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.3390\/ijms22137114","article-title":"Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer","volume":"22","author":"Zulkifli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2023.115939_b0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2018.01.059","article-title":"Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells","volume":"420","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"issue":"7424","key":"10.1016\/j.bcp.2023.115939_b0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature11706","article-title":"How cancer metabolism is tuned for proliferation and vulnerable to disruption","volume":"491","author":"Schulze","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2023.115939_b0160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.molcel.2016.02.011","article-title":"Mitochondria and Cancer","volume":"61","author":"Zong","year":"2016","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.bcp.2023.115939_b0165","first-page":"857","article-title":"Mitochondria","volume":"3","author":"Burke","year":"2017","journal-title":"Bioenergetics and Apoptosis in Cancer, Trends Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2023.115939_b0170","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0022-5347(05)00651-8","article-title":"The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer","volume":"175","author":"Pelzer","year":"2006","journal-title":"J Urol"},{"issue":"Pt 20","key":"10.1016\/j.bcp.2023.115939_b0175","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1242\/jcs.064915","article-title":"ATF3, an adaptive-response gene, enhances TGFbeta signaling and cancer-initiating cell features in breast cancer cells","volume":"123","author":"Yin","year":"2010","journal-title":"J Cell Sci"},{"issue":"7","key":"10.1016\/j.bcp.2023.115939_b0180","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1582-4934.2011.01401.x","article-title":"Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells","volume":"16","author":"Liu","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.bcp.2023.115939_b0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13046-018-0919-8","article-title":"ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression","volume":"37","author":"Chen","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.bcp.2023.115939_b0190","doi-asserted-by":"crossref","first-page":"32899","DOI":"10.1074\/jbc.M305456200","article-title":"Regulation of proglucagon transcription by activated transcription factor (ATF) 3 and a novel isoform, ATF3b, through the cAMP-response element\/ATF site of the proglucagon gene promoter","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.bcp.2023.115939_b0195","doi-asserted-by":"crossref","first-page":"20020","DOI":"10.1074\/jbc.M200727200","article-title":"The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression","volume":"277","author":"Allen-Jennings","year":"2002","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.bcp.2023.115939_b0200","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/db10-1743","article-title":"Impaired expression of the inducible cAMP early repressor accounts for sustained adipose CREB activity in obesity","volume":"60","author":"Favre","year":"2011","journal-title":"Diabetes"},{"issue":"13","key":"10.1016\/j.bcp.2023.115939_b0205","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.94.13.6658","article-title":"c-Myc transactivation of LDH-A: implications for tumor metabolism and growth","volume":"94","author":"Shim","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"10.1016\/j.bcp.2023.115939_b0210","doi-asserted-by":"crossref","first-page":"32529","DOI":"10.1074\/jbc.271.51.32529","article-title":"Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1","volume":"271","author":"Semenza","year":"1996","journal-title":"J Biol Chem"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:21:08Z","timestamp":1762096868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223005324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"alternative-id":["S0006295223005324"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115939","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115939"}}